Blood test may unlock long COVID secrets
NCT ID NCT05758480
First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This completed study took blood samples from 62 people with Long COVID and compared them to healthy controls. Researchers looked for specific immune and metabolic patterns that might explain why symptoms persist. The goal is to better understand Long COVID, not to test a treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify biological markers that define Long COVID, potentially leading to better diagnosis and future treatments.
- What could go wrong
- This is a small, observational study that only looks for patterns in blood samples. It does not test any treatment, so it may not directly lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
62 people
The number who actually took part.
- Started
-
May 2023
- Finished
-
Nov 2025
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
A/ Inclusion Criteria: * For all patients: * Age \> 18 years * Symptomatic COVID-19 diagnosed after 01JAN2021, confirmed by RT-PCR or Antigen test * Last SARS-CoV-2 infection diagnosed more than 12 weeks before inclusion * Patient covered by the French health insurance * Signature of the informed consent * For patient with Long COVID : * At least one of the following symptoms during the week preceding inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia) * Absence of Return to Usual Health after SARS-CoV-2 infection (patient declaration) * Absence of alternative diagnosis for the symptoms * For COVID-19 recovered patient (Control) : * None of the following symptoms in the 3 week before inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia) * Return to Usual Health after SARS-CoV-2 infection (patient declaration) B/ Exclusion Criteria: * History of severe COVID-19 (Hospitalization) * Symptoms caused by sequelae of SARS-CoV-2 infection (in particular, persistence of lung parenchymal abnormalities : pulmonary fibrosis, persistent alveolitis on CT-Scan) * Significant Depression or anxiety symptoms, as assessed by a \> 10 score on the A or D items of the Hospital anxiety and depression scale (HAD) * Presence of one of the following diseases: * Inborn errors of metabolism * estimated Glomerular filtration rate \< 30 ml/min (MDRD) * Autoimmune disease * Immunosuppressive treatment or immune deficiency * Symptomatic heart failure * Respiratory failure (COPD stage ≥ 3 or oxygen therapy) * Solid cancer or active blood disease * Severe malnutrition (albumin \< 30 g/L or weight loss ≥10% in 6 months) * Obesity with BMI ≥ 35 kg/m² * Diabetes not controlled by diet alone * Pregnant, breastfeeding or parturient women * Deprivation of liberty by judicial or administrative decision * Mandatory Psychiatric Care * Protected by decision of law * Unable to express consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Long COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Angers University Hospital
Angers, 49933, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can slow breathing retrain the nervous system to fight long COVID?
- Can a brain zapping headset restore focus after long COVID?
- Mindfulness may offer relief for long COVID sufferers
- Can wearables decode the mystery of fatigue?
- Beetroot juice: a natural boost against long COVID fatigue?
- A One-Two punch for long COVID? supplement and therapy put to the test